Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04840667




Registration number
NCT04840667
Ethics application status
Date submitted
7/07/2020
Date registered
12/04/2021
Date last updated
17/06/2024

Titles & IDs
Public title
A Study of Replagal in Treatment-naïve Adults With Fabry Disease
Scientific title
A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
Secondary ID [1] 0 0
2018-004689-32
Secondary ID [2] 0 0
SHP675-301
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Fabry Disease 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - REPLAGAL

Experimental: REPLAGAL - Participants will receive REPLAGAL 0.2 milligram per kilogram (mg/kg) body weight of intravenous (IV) infusion Every Other Week (EOW) for 104 weeks.


Treatment: Drugs: REPLAGAL
Participants will receive REPLAGAL 0.2 mg/kg body weight of IV infusion for 104 weeks.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Renal Function at Week 104
Timepoint [1] 0 0
Baseline, Week 104
Primary outcome [2] 0 0
Change From Baseline in Cardiac Structure at Week 104
Timepoint [2] 0 0
Baseline, Week 104
Secondary outcome [1] 0 0
Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) up to Week 104
Timepoint [1] 0 0
From Baseline up to Week 104
Secondary outcome [2] 0 0
Annualized Rate of Change in Left Ventricular Mass Index (LVMI) up to Week 104
Timepoint [2] 0 0
From Baseline up to Week 104
Secondary outcome [3] 0 0
Change From Baseline in eGFR up to Week 104
Timepoint [3] 0 0
From Baseline up to Week 104
Secondary outcome [4] 0 0
Change From Baseline in LVMI up to Week 104
Timepoint [4] 0 0
From Baseline up to Week 104
Secondary outcome [5] 0 0
Change From Baseline in Proteinuria up to Week 104
Timepoint [5] 0 0
From Baseline up to Week 104
Secondary outcome [6] 0 0
Change From Baseline in Cardiac Fibrotic Segments up to Week 104
Timepoint [6] 0 0
From Baseline up to Week 104
Secondary outcome [7] 0 0
Change From Baseline in Interventricular Septal End-Diastolic Thickness and Posterior Wall Thickness in Diastole up to Week 104
Timepoint [7] 0 0
From Baseline up to Week 104
Secondary outcome [8] 0 0
Change From Baseline in Plasma Globotriaosylsphingosine (Lyso-Gb3) up to Week 104
Timepoint [8] 0 0
From Baseline up to Week 104
Secondary outcome [9] 0 0
Number of Participants With Adverse Events (AEs)
Timepoint [9] 0 0
From start of study drug administration up to follow-up visit (i.e., up to Week 106)
Secondary outcome [10] 0 0
Number of Participants Who Will Develop Anti-drug Antibodies (ADA) to REPLAGAL
Timepoint [10] 0 0
From Baseline up to Week 104

Eligibility
Key inclusion criteria
* The participant must voluntarily sign an Institutional Review Board (IRB)/Independent Ethics Committee/Research Ethics Board approved informed consent form after all relevant aspects of the study have been explained and discussed with the participant.
* The participant has Fabry disease as confirmed at screening by the following criteria using a dried blood spot (DBS) assay:

1. For male participants, Fabry disease is confirmed by a deficiency of alpha-galactosidase A (GLA) activity and a mutation in the GLA gene
2. For female participants, Fabry disease is confirmed by a mutation in the GLA gene
* The participant is 18 to 65 years of age, inclusive.
* Female participants must have a negative pregnancy test at screening.
* Female participants of child-bearing potential must agree to use a medically acceptable method of contraception at all times during the study and for at least 14 days after the final study infusion; the methods of acceptable contraception are listed in the protocol.
* The participant is deemed, as determined by the investigator, to have adequate general health to undergo the specified protocol-related procedures and to have no safety or medical contraindications for participation.
* The participant has not received any treatment (approved or investigational) specific to Fabry disease, such as enzyme replacement therapy (ERT), chaperone therapy, or substrate reduction therapy.
* The participant must have an eGFR of 45 to 120 milliliter per minute per 1.73 square meter (mL/min/1.73 m^2); eGFR will be calculated by a Shire-designated laboratory using the CKD-EPI formula. If the eGFR measurement at screening is not within the range, a second eGFR measurement may be completed and, if in range, used as the screening value. If a second measurement is taken, a minimum of 1 week and maximum of 30 days should separate it from the first. This inclusion criterion follows the European Guidelines for Treatment of Fabry Disease and Kidney Disease Improving Global Outcomes guidelines for classification of renal disease.
* The participant has left ventricular hypertrophy (LVH), where LVH is defined as left ventricular mass index (LVMI) greater than (>) 50 gram per square meter (g/m^2.7) confirmed by cardiac magnetic resonance imaging (cMRI) at screening. The cMRI value at screening will serve as the baseline value.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* In the opinion of the investigator, the participant's life expectancy is less than or equal to (<=) 5 years.
* The participant has undergone or is scheduled to undergo kidney transplantation or is currently on dialysis, or has any signs or symptoms of end stage renal disease.
* Urine protein/creatinine ratio (PCR) greater than (>) 1.5 milligram per milligram (mg/mg).
* Participants who have clinically relevant history of allergy or signs or symptoms of severe hypersensitivity, (including hypersensitivity to the REPLAGAL active substance or any of the excipients), which in the investigator's judgment, will substantially increase the participant's risk if he or she participates in the study.
* Cardiac fibrosis involving more than 2 segments, as determined by cMRI at screening.
* In the opinion of the investigator, the participant has non-Fabry disease-related cause of end-organ (renal, cardiac, central nervous system) dysfunction/failure or is receiving medications that may affect the rate of disease progression, as assessed by cardiac and/or renal measures.
* The participant has a positive test at screening for hepatitis B surface antigen, positive test for hepatitis B core antibody, positive test for hepatitis C (HCV) antibody with confirmation by HCV-ribonucleic acid polymerase chain reaction testing, or positive test for human immunodeficiency virus antibody.
* Treatment with REPLAGAL at any time prior to the study.
* Prior treatment with any of the following medications:

1. FABRAZYME (agalsidase beta) and its biosimilars
2. GLYSET (miglitol)
3. ZAVESCA (miglustat)
4. CERDELGA (eliglustat)
5. GALAFOLD (migalastat)
6. Any investigational product for treatment of Fabry disease
* Treatment at any time during the study with the following medications:

1. Chloroquine
2. Amiodarone
3. Monobenzone
4. Gentamicin
* The participant is pregnant or lactating.
* The participant has a body mass index > 39 kilogram per square meter (kg/ m^2). (Body mass index [BMI] = kg/ m^2).
* The participant is treated or has been treated with any investigational drug within 30 days of study start.
* The participant is unable to understand the nature, scope, and possible consequences of the study.
* The participant is unable to comply with the protocol, eg, uncooperative with protocol schedule, refusal to agree to all of the study procedures, inability to return for evaluations, or is otherwise unlikely to complete the study, as determined by the investigator.

Study design
Purpose of the study
Treatment
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/12/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
16/12/2022
Sample size
Target
Accrual to date
Final
17
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
Canada
State/province [1] 0 0
Calgary
Country [2] 0 0
Canada
State/province [2] 0 0
Halifax
Country [3] 0 0
Finland
State/province [3] 0 0
Turku

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Shire
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
Shire
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT04840667